PHILADELPHIA, PA / ACCESS Newswire / January 28, 2026 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Neumora Therapeutics, Inc. (NASDAQ:NMRA) ("Neumora") on behalf of the company’s long-term shareholders.
Click here to submit your information to the firm and to receive additional information about your legal rights and options: https://kaskelalaw.com/case/neumora/
Neumora is a clinical-stage biopharmaceutical company that seeks to develop novel therapies for depression and other mental illnesses. In September 2023, Neumora completed its initial public offering ("IPO") of common stock, selling 14.7 million shares of stock to investors at a price of $17.00 per share. Leading up to the IPO, Neumora’s most advanced drug candidate was navacaprant or "Nava," a once-daily pill developed to treat major depressive disorder ("MDD").
Recently a federal securities fraud complaint was filed against Neumora on behalf of certain investors who purchased shares of the company’s stock pursuant and/or traceable to the company’s September 2023 IPO. According to the complaint, although the Offering Documents filed with the SEC in connection with the IPO promoted Nava as a potential blockbuster antidepressant, the defendants’ positive portrayal of Nava’s Phase 2 clinical trial and its prospects for FDA approval were materially false and misleading, and omitted material facts.
As further detailed in the complaint, investors gradually learned the truth about sixteen months after the IPO, when Neumora was forced to disclose disastrous Phase 3 trial results demonstrating that Nava was completely ineffective in men. In response, Neumora’s stock price plunged 80% in a single day, from a close of $10.60 on December 31, 2024, to a close of $1.97 on January 2, 2025, the following trading day.
In light of the foregoing, Kaskela Law is investigating whether Neumora’s officers and directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
Current Neumora shareholders who have continuously held NMRA shares since at least January 1, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) to receive additional information about this investigation and their legal rights and options at (484) 229 – 0750, via email at abell@kaskelalaw.com, or by clicking on the following link (or if necessary, by copying and pasting the link into your browser):
https://kaskelalaw.com/case/neumora/
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis, and has assisted investors in recovering over $500 million. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.
SOURCE: Kaskela Law LLC
View the original press release on ACCESS Newswire
COMTEX_472506145/2457/2026-01-28T07:59:13